Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 4/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29193191 | 0.81 | CBLB (0.42) | CBLBROS1 | |
| SCHEMBL24818750 | 0.79 | CBLB (0.45) | CBLBROS1MAP3K5 | |
| SCHEMBL29920812 | 0.79 | CBLB (0.43) | CBLBROS1 | |
| SCHEMBL24818748 | 0.79 | CBLB (0.43) | CBLBROS1 | |
| SCHEMBL30792029 | 0.78 | CBLB (0.44) | CBLBROS1MAP3K5TTK | |
| SCHEMBL29920131 | 0.76 | CBLB (0.62) | CBLB | |
| SCHEMBL30792122 | 0.74 | MAPK13 (0.42) | CBLB | |
| SCHEMBL29189939 | 0.73 | CBLB (0.36) | CBLB | |
| SCHEMBL29920297 | 0.72 | CBLB (0.69) | CBLB | |
| SCHEMBL27086339 | 0.72 | CBLB (0.69) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022217276-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885PRMT5 773/4885WDR77 371/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885PRMT5 773/4885WDR77 371/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | CBLB 1/4885PRMT5 773/4885WDR77 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.